GNF-5837 是一种有效的,选择性的,口服生物利用的泛TRK抑制剂,在 Ba/F3 细胞中显示出抗增殖作用 (对Tel-TrkC,Tel-TrkB和Tel-TrkA的IC50值分别为 7 nM,9 nM 和 11 nM)。
.
生物活性 | GNF-5837 is a potent, selective, and orally bioavailable pan-tropomyosin receptor kinase (TRK)inhibitor which display antiproliferative effects in cellular Ba/F3 assays (IC50values of 7 nM, 9 nM and 11 nM for cells containing the fusion proteinsTel-TrkC,Tel-TrkBandTel-TrkA, respectively)[1]. |
IC50& Target | TrkB 9 nM (IC50) | TrkC 7 nM (IC50) | TrkA 11 nM (IC50) |
|
体外研究 (In Vitro) | GNF-5837 (0.1-500 nM; 72-144 hours; GOT1 cells) treatment decreases cell viability in a time- and dose-dependent manner in GOT1 cells[2]. GNF-5837 (5-500 nM; 24 hours; GOT1 cells) causes downregulation of PI3K-Akt-mTOR signaling, Ras-Raf-MEK-ERK signaling[2]. GNF-5837 (5-500 nM; 72 hours; GOT1 cells) treatment induces G1 cell cycle arrest[2]. GNF-5837 (500 nM; 144 hours; GOT1 cells) treatment increases apoptotic cell death[2].
Cell Viability Assay[2] Cell Line: | GOT1 cells | Concentration: | 0.1 nM , 0.5 nM , 1 nM , 5 nM , 10 nM , 50 nM , 100 nM and 500 nM | Incubation Time: | 72 hours, 96 hours and 144 hours | Result: | Cell viability assay determined a clear decrease of GOT1 cell viability in a time- and dose- dependent manner. |
Western Blot Analysis[2] Cell Line: | GOT1 cells | Concentration: | 5 nM, 50 nM and 500 nM | Incubation Time: | 24 hours | Result: | Significant levels of TrkA expression, faint TrkC expression and no TrkB expression. |
Cell Cycle Analysis[2] Cell Line: | GOT1 cells | Concentration: | 5 nM, 500 nM | Incubation Time: | 72 hours | Result: | Induced G1 cell cycle arrest. |
Apoptosis Analysis[2] Cell Line: | GOT1 cells | Concentration: | 500 nM | Incubation Time: | 144 hours | Result: | Induced apoptosis. |
|
体内研究 (In Vivo) | GNF-5837 (25-100 mg/kg; oral administration; once daily; for 10 days; mice) treatment inhibits tumor growth in a mouse xenograft model derived from RIE cells expressing both TRKA and NGF[1].
Animal Model: | Mouse xenograft model[1] | Dosage: | 25 mg/kg, 50 mg/kg, 100 mg/kg | Administration: | Oral administration; once daily; for 10 days | Result: | 72 and 100% tumor regression was observed at 50 and 100 mg/kg, respectively. At 25 mg/kg, only partial tumor growth inhibition was achieved. |
|
分子量 | |
性状 | |
Formula | |
CAS 号 | |
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | Powder | -20°C | 3 years | | 4°C | 2 years | In solvent | -80°C | 6 months | | -20°C | 1 month |
|
溶解性数据 | In Vitro: DMSO : ≥ 32 mg/mL(59.76 mM) *"≥" means soluble, but saturation unknown. 配制储备液 1 mM | 1.8674 mL | 9.3372 mL | 18.6745 mL | 5 mM | 0.3735 mL | 1.8674 mL | 3.7349 mL | 10 mM | 0.1867 mL | 0.9337 mL | 1.8674 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百 分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂: 10% DMSO 40%PEG300 5%Tween-80 45% saline Solubility: ≥ 2.5 mg/mL (4.67 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (4.67 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。 2. 请依序添加每种溶剂: 10% DMSO 90% (20%SBE-β-CDin saline) Solubility: 2.5 mg/mL (4.67 mM); Suspended solution; Need ultrasonic
此方案可获得 2.5 mg/mL (4.67 mM) 的均匀悬浊液,悬浊液可用于口服和腹腔注射。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。 *以上所有助溶剂都可在本网站选购。
|